Bristol Myers Squibb CEO expects Zeposia to renew company's medicine portfolio

"Zeposia is one of the key medicines that we count on for the renewal of our portfolio, and things are progressing very well," Bristol Myers Squibb CEO Giovanni Caforio said of the phase three trial of a bowel disease treatment.
Tue, Jan 12 20211:41 PM EST